Novavax, Inc. (NASDAQ:NVAX) persists its position slightly strong in context of buying side, while shares price plunged -2.90% during latest trading session. The returns on assets of firm also on noticeable level, it has ROA of -56.80%, which signifies how profitable a firm is relative to its total assets.
Novavax, Inc., (NVAX) announced its financial results for the fourth quarter and twelve months ended December 31, 2016. “We`ve made significant progress executing on the path forward that we outlined in late 2016,” said Stanley C. Erck, President and CEO. “For the remainder of the year we will focus on the ongoing Phase 3 trial of our RSV F Vaccine for infants via maternal immunization and on understanding the results of our Phase 2 immunogenicity trial in older adults, along with a deeper understanding of the Resolve Phase 3 trial results we reported last September. We also plan on moving our Zika and nanoparticle influenza vaccine programs into the clinic later this year.”
Experts’ Critical Views
The NVAX held a rough session during the week but was ready to get some critical analysis. The stock was assessed by a pool of analysts at WSJ and came out with some serious outcomes not to be avoided before making investment. The NVAX ratings chart showed that 6 gave HOLD ratings for the current month. For stocks’ current month, 1 analyst opted for BUY ratings. The stock price target chart showed average price target of 3.70 as compared to current price of 1.34.
Taking look on per share earnings estimates, its next year first quarter current estimate trend for EPS was for $-0.16 and on annual basis FY 2016 estimate trends at current was for $-0.62 as compared to one month ago of $-0.63, and for next year per share earnings estimates have $-0.64.
The co is presenting price to cash flow as 1.55, the low single digit may indicate stock is undervalued and vice versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.
To make strengthen these views, the active industry firm has Quick Ratio of 4.30, which indicates firm has sufficient short-term assets to cover its immediate liabilities. The firm has price volatility of 3.35% for a week and 6.34% for a month. Its beta stands at 1.96 times. Narrow down four to firm performance, its weekly performance was -8.22% and monthly performance was -17.28%.